Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Superiority of Glimepiride Over Sitagliptin in Naive Type 2 Diabetes Patients

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: GLIMEPIRIDE (HOE490)
Drug: SITAGLIPTIN

First Posted Date: 2009-08-12

Last Posted Date: 2010-11-30

Lead Sponsor: Sanofi

Target Recruit Count: 400

Registration Number: NCT00957060

Locations: 🇲🇽
Sanofi-Aventis Administrative Office, Col. Coyoacan, Mexico

Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: irbesartan/amlodipine
Drug: irbesartan

First Posted Date: 2009-08-12

Last Posted Date: 2010-10-26

Lead Sponsor: Sanofi

Target Recruit Count: 435

Registration Number: NCT00957554

Locations: 🇲🇽
Sanofi-Aventis Investigational Site Number 48401, Mérida, Mexico
🇲🇽
Sanofi-Aventis Investigational Site Number 48407, San Luis Potosi, Mexico
🇨🇴
Sanofi-Aventis Investigational Site Number 17003, Cartagena, Colombia

and more 35 locations

Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: irbesartan/amlodipine
Drug: amlodipine

First Posted Date: 2009-08-11

Last Posted Date: 2010-10-26

Lead Sponsor: Sanofi

Target Recruit Count: 406

Registration Number: NCT00956644

Locations: 🇨🇴
Sanofi-Aventis Investigational Site Number 17004, Barranquilla, Colombia
🇨🇱
Sanofi-Aventis Investigational Site Number 15203, Santiago, Chile
🇧🇷
Sanofi-Aventis Investigational Site Number 076-002, São Paulo, Brazil

and more 37 locations

A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

Phase 2

Completed

Conditions: Influenza
Swine-origin A/H1N1 Influenza

Interventions: Biological: Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant
Biological: Monovalent Subvirion A/H1N1 influenza vaccine
Biological: Normal saline solution

First Posted Date: 2009-08-06

Last Posted Date: 2011-10-03

Lead Sponsor: Sanofi

Target Recruit Count: 548

Registration Number: NCT00952276

Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary Care

Phase 4

Terminated

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: INSULIN GLARGINE (HOE901)
Drug: Oral Anti Diabetics (OAD)

First Posted Date: 2009-07-31

Last Posted Date: 2011-11-10

Lead Sponsor: Sanofi

Target Recruit Count: 25

Registration Number: NCT00950534

Locations: 🇦🇺
Sanofi-Aventis Administrative Office, Macquarie Park, Australia

Irbesartan and Amlodipine Combination in Controlling Blood Pressure

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: IRBESARTAN (SR47436)
Drug: Irbesartan / Amlodipine
Drug: Placebo
Drug: Amlodipine

First Posted Date: 2009-07-31

Last Posted Date: 2011-01-05

Lead Sponsor: Sanofi

Target Recruit Count: 270

Registration Number: NCT00950066

Locations: 🇨🇳
Sanofi-Aventis Administrative Office, Taipei, Taiwan

Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin Glargine (HOE901) [Lantus]
Drug: Glimepiride
Drug: human insulin [NPH]

First Posted Date: 2009-07-30

Last Posted Date: 2012-08-21

Lead Sponsor: Sanofi

Target Recruit Count: 708

Registration Number: NCT00949442

Locations: 🇰🇼
Investigational Site Number 414001, Kuwait, Kuwait
🇷🇴
Investigational Site Number 642005, Iasi, Romania
🇷🇴
Investigational Site Number 642010, Oradea, Romania

and more 84 locations

Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes Patients

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin Glargine (HOE901)/NPH Insulin

First Posted Date: 2009-07-17

Last Posted Date: 2012-11-22

Lead Sponsor: Sanofi

Target Recruit Count: 345

Registration Number: NCT00941369

Locations: 🇩🇪
Sanofi-Aventis Administrative Office, Berlin, Germany

Benign Prostatic Hyperplasia in Taiwan

Not Applicable

Completed

Conditions: Prostatic Diseases

Interventions: Drug: Alfuzosin (XATRAL® - SL770499)

First Posted Date: 2009-07-17

Last Posted Date: 2010-03-30

Lead Sponsor: Sanofi

Target Recruit Count: 362

Registration Number: NCT00941343

Locations: 🇨🇳
Sanofi-Aventis Administrative Office, Taipei, Taiwan

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: gemcitabine/carboplatin
Drug: Iniparib

First Posted Date: 2009-07-14

Last Posted Date: 2013-09-19

Lead Sponsor: Sanofi

Target Recruit Count: 519

Registration Number: NCT00938652

Locations: 🇺🇸
Research Site, Yakima, Washington, United States
🇺🇸
Reserach Site, Columbia, South Carolina, United States
🇺🇸
Research Sites, Seattle, Washington, United States

Home Terms & Conditions Privacy Policy